Documenti analoghi

• Prevalence of SGLT2 inhibitor and GLP1 receptor agonist prescriptions in type 2 diabetes patients with and without chronic kidney disease: Analysis of an Australian primary care dataset
  di: Hannah Wallace, et al.
  Pubblicazione: (2025)
• Availability and readiness of health facilities for chronic kidney disease, diabetes and cardiovascular disease in Ethiopia: Evidence from service provision assessment data
  di: Daniel Bekele Ketema, et al.
  Pubblicazione: (2025)
• Variability in HbA1c and the risk of major clinical outcomes in type 2 diabetes with chronic kidney disease: Post hoc analysis from the CREDENCE trial
  di: Ying Zhu, et al.
  Pubblicazione: (2025)
• Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines
  di: Kaitlin J. Mayne, et al.
  Pubblicazione: (2024)
• Machine learning for prediction of chronic kidney disease progression: Validation of the Klinrisk model in the CANVAS Program and CREDENCE trial
  di: Navdeep Tangri, et al.
  Pubblicazione: (2024)